DAVID BATES to Angiotensin-Converting Enzyme Inhibitors
This is a "connection" page, showing publications DAVID BATES has written about Angiotensin-Converting Enzyme Inhibitors.
Connection Strength
0.595
-
An evaluation of risk factors for adverse drug events associated with angiotensin-converting enzyme inhibitors. J Eval Clin Pract. 2004 Nov; 10(4):499-509.
Score: 0.213
-
Development and validation of a clinical prediction rule for angiotensin-converting enzyme inhibitor-induced cough. J Gen Intern Med. 2004 Jun; 19(6):684-91.
Score: 0.207
-
Association of Changes in Creatinine and Potassium Levels After Initiation of Renin Angiotensin Aldosterone System Inhibitors With Emergency Department Visits, Hospitalizations, and Mortality in Individuals With Chronic Kidney Disease. JAMA Netw Open. 2018 11 02; 1(7):e183874.
Score: 0.141
-
Physician and patient tools to improve chronic kidney disease care. Am J Manag Care. 2018 04 01; 24(4):e107-e114.
Score: 0.034